Alnylam Pharmaceuticals, Inc.
ALNY
NASDAQ·Healthcare·Biotechnology·Mkt cap $35.6B
$266.11
▲ +0.61%
P/E
44.72
Mkt Cap
$35.6B
52-Wk Range
$197.81–$495.55
52-Week Range
$197.81 - $495.55
P/E
Fwd P/E
Beta
Div Yield
Avg Vol
Shares Out
Mkt Cap
Price action
Price chart
Down 41.5% over the trailing year
Total returns
Price performance
Total return across standard periods - splits & dividends adjusted by FMP. Periods longer than 1Y show annualized in the tooltip.
Why we rate it this way
The thesis at a glance
Bull and bear case · plain-English context across the five lenses we evaluate.
Bull Case
5 reasons
- Proprietary RNAi platform technology with established clinical efficacy and safety profile
- First-mover advantage in RNA interference therapeutics with three FDA-approved products
- Strategic partnerships with pharmaceutical giants enabling expanded development and commercialization
- Deep pipeline of late-stage candidates addressing high-unmet-need genetic and chronic diseases
- Intellectual property portfolio protecting core RNAi technology and specific therapeutic applications
Bear Case
2 risks
- Low volatility (beta 0.3).
- Growth premium of 1.8x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Growth
Moderate growth ahead
Strong revenue growth (65% YoY)
Value
Growth premium of 1.8x vs Biotech & Therapeutics peers. Elevated but may be justified by growth trajectory.
Momentum
Weak
-8.9% over 3m
Quality
Excellent
High-growth business (95% revenue growth, 80% gross margin). Profitable with strong growth momentum.
Dividend
None
No dividend
Smart-money signal
Who's buying ALNY right now
Insider Form 4s, 13F institutional filings, and Congressional disclosures - at a glance.
Earnings track record
Recent earnings results
AI-summarized recap of last quarter, plus the surprise on every print.
Next: Oct 29, 2026
JUL 30, 2026
Reported EPS of $1.21 vs $1.63 consensus (-25.8% surprise). Revenue of $1.3B vs $1.3B expected (-2.4%).
EPS surprise · last 4Q
0 of 1 beats
Estimate
Actual
Q3 26
-25.8%
Revenue trend · last 8Q
—
+35%
+20%
+17%
+149%
+85%
+96%
+67%
Q3 24
Q4 24
Q1 25
Q2 25
Q3 25
Q4 25
Q1 26
Q2 26
$500.9M
$593.2M
$594.2M
$773.7M
$1.2B
$1.1B
$1.2B
$1.3B
Margins · last 8Q
Gross
-74.1%
Operating
17.9%
Profit
12.7%
Wall Street consensus
10 analysts · 80% Buy
Live ratings and price targets aggregated across covering analysts.
Buy
80%
Hold
20%
Sell
0%
Median Price Target
$470.00
▲ +76.6% vs $266.11
Latest: Bernstein · Aug 31, 2026
1 analyst covering
vs Industry
How ALNY stacks vs Biotechnology
Stock metrics vs industry averages. Green = better than industry.
Industry comparison data unavailable for this stock.
Related